Drug Trial Radar · NCT06432296
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
312
Actual
Start
Mar 25, 2024
Primary completion
Aug 22, 2025
Study completion Dec 12, 2026
Sponsor
- Lead sponsor
- Wuhan YZY Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to Paracentesis alone in Patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors.
Conditions
- Malignant Ascites
Interventions
M701Drug
Intra-peritoneal infusion of M701 in experimental group (M701 group\_
paracentesisProcedure
Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
Primary outcomes
What the sponsor says the trial is designed to measure.
- PuFSTime frame: Time from the end of drainage of ascites at C1V4 to the start of the next drainage or death (up to 6 months)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.